|
Zedoresertib Clinical Trials
2 actively recruiting trials across 2 locations
Also known as: Debio 0123
Pipeline
Phase 1: 1Phase 1/2: 1
Top Sponsors
- Debiopharm International SA2
Indications
- Cancer2
- Astrocytoma, Grade III1
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype1
- Advanced Solid Tumor1
Los Angeles, California1 trial
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
# 1019, UCLA, Westwood Cancer Center
Phase 1
Chicago, Illinois1 trial
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.